| Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
|
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
| Therapy for lower-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Therapy-related myelodysplastic syndromes in the genomics era |
|
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
|
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment |
|
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
|
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
